Fabrication and evaluation a transferrin receptor targeting nano-drug carrier for cerebral infarction treatment

References

• Lee SJ, Cheong JS, Ryu HU, et al. Recanalization of chronic occlusion of the middle cerebral artery with tissue plasminogen activator treatment: a case report. Clin Neuropharmacol. 2018;21:0000000000000282.
   Google Scholar
• Chen C, Mu X-Y, Zhou Y, et al. Ginsenoside Rg1 enhances the resistance of hematopoietic stem/progenitor cells to radiation-induced aging in mice. Acta Pharmacol Sin. 2014;35:143–150.
   PubMed Web of Science ®Google Scholar
• Wang J, Xu H-M, Yang H-D, et al. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem Int. 2009;54:43–48.
   PubMed Web of Science ®Google Scholar
• Wang J, Li D, Hou J, et al. Protective effects of geniposide and ginsenoside Rg1 combination treatment on rats following cerebral ischemia are mediated via microglial microRNA1555p inhibition. Mol Med Rep. 2018;17:3186–3193.
   PubMed Web of Science ®Google Scholar
• Xie C-L, Li J-H, Wang W-W, et al. Neuroprotective effect of ginsenoside-Rg1 on cerebral ischemia/reperfusion injury in rats by downregulating protease-activated receptor-1 expression. Life Sci. 2015;121:145–151.
   PubMed Web of Science ®Google Scholar
• Li YB, Wang Y, Tang JP, et al. Neuroprotective effects of ginsenoside Rg1-induced neural stem cell transplantation on hypoxic-ischemic encephalopathy. Neural Regen Res. 2015;10:753–759.
   PubMed Web of Science ®Google Scholar
• Fernández-Moriano C, González-Burgos E, Iglesias I, et al. Evaluation of the adaptogenic potential exerted by ginsenosides Rb1 and Rg1 against oxidative stress-mediated neurotoxicity in an in vitro neuronal model. PLoS One 2017;12:e0182933.
   PubMed Web of Science ®Google Scholar
• Xie CL, Wang WW, Xue XD, et al. A systematic review and meta-analysis of Ginsenoside-Rg1 (G-Rg1) in experimental ischemic stroke. Sci Rep. 2015;5:7790.
   PubMed Web of Science ®Google Scholar
• Shen HH. Core concept: circumventing the blood-brain barrier. Proc Natl Acad Sci USA. 2017;114:11261–11263.
   PubMed Web of Science ®Google Scholar
• Nogueira-Librelotto DR, Codevilla CF, Farooqi A, et al. Transferrin-conjugated nanocarriers as active-targeted drug delivery platforms for cancer therapy. CPD. 2017;23:454–466.
   Web of Science ®Google Scholar
• Li H, Sun H, Qian ZM. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci. 2002;23:206–209.
   PubMed Web of Science ®Google Scholar
• Han L, Li J, Huang S, et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials. 2011;32:2989–2998.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Fu Y, Kao WJ, et al. Transbuccal delivery of CNS therapeutic nanoparticles: synthesis, characterization, and in vitro permeation studies. ACS Chem Neurosci. 2011;2:676–683.
   PubMed Web of Science ®Google Scholar
• Li Y, He H, Jia X, et al. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33:3899–3908.
   PubMed Web of Science ®Google Scholar
• Shen J, Zhao Z, Shang W, et al. Ginsenoside Rg1 nanoparticle penetrating the blood-brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction. IJN. 2017;12:6477–6486.
   Web of Science ®Google Scholar
• Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of monoclonal antibody products: a simulated case study correlating antibody induction with clinical outcomes. Biologicals. 2015;43:307–317.
   PubMed Web of Science ®Google Scholar
• Waldmann H. Human monoclonal antibodies: the residual challenge of antibody immunogenicity. Methods Mol Biol. 2014;1060:1–8.
   PubMedGoogle Scholar
• Loureiro JA, Gomes B, Fricker G, et al. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. Colloids Surf B Biointerfaces. 2016;145:8–13.
   PubMed Web of Science ®Google Scholar
• Huang N, et al. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Abeta generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice. Oncotarget. 2017;8:81001–81013.
   PubMedGoogle Scholar
• Sahin A, Yoyen-Ermis D, Caban-Toktas S, et al. Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells. J Microencapsul. 2017;34:659–666.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang T, Li Q, et al. Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo. Int J Nanomedicine. 2016;11:2663–2673.
   PubMed Web of Science ®Google Scholar
• Geng X, Ye H, Feng Z, et al. Synthesis and characterization of cisplatin-loaded, EGFR-targeted biopolymer and in vitro evaluation for targeted delivery. J Biomed Mater Res A. 2012;100:2839–2848.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chang J, Zhao Y, et al. Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis. Int J Nanomedicine. 2018;13:2051–2064.
   PubMed Web of Science ®Google Scholar
• Gabriel CM, Keener M, Gallou F, et al. Amide and peptide bond formation in water at room temperature. Org Lett. 2015;17:3968–3971.
   PubMed Web of Science ®Google Scholar
• Zhang L, Geng X, Zhou J, et al. Fabrication of poly(gamma-glutamic acid)-based biopolymer as the targeted drug delivery system with enhanced cytotoxicity to APN/CD13 over-expressed cells. J Drug Target. 2015;23:453–461.
   PubMed Web of Science ®Google Scholar
• Luo L, Lü L, Lu Y, et al. Effects of hypoxia on progranulin expression in HT22 mouse hippocampal cells. Mol Med Rep. 2014;9:1675–1680.
   PubMed Web of Science ®Google Scholar
• Jiang RG, Zhang XQ, Eyzaguirre C. Hypoxia induced by Na2S2O4 increases [Na+]i in mouse glomus cells, an effect depressed by cobalt. Experiments with Na+-selective microelectrodes and voltage-clamping. Brain Res. 1998;797:197–208.
   PubMed Web of Science ®Google Scholar
• Zhao L, et al. Protective effect of rhGLP-1 (7-36) on brain ischemia/reperfusion damage in diabetic rats. Brain Res. 2015;30:153–159.
   Web of Science ®Google Scholar
• Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol. 2003;84:187–192.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S. DLS and zeta potential – what they are and what they are not? J Control Release. 2016;235:337–351.
   PubMed Web of Science ®Google Scholar
• Haseloff RF, Dithmer S, Winkler L, et al. Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects. Semin Cell Dev Biol. 2015;38:16–25.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Y, Akamatsu Y, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014;115:138–156.
   PubMed Web of Science ®Google Scholar
• Kumagai M, et al. A therapeutic angiogenesis of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel sheets in a canine chronic myocardial infarction model. Heart Vessels. 2018;14:018–1185.
   Google Scholar
• Ergul A, Alhusban A, Fagan SC. Angiogenesis: a harmonized target for recovery after stroke. Stroke. 2012;43:2270–2274.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. Neurotherapeutics. 2005;2:3–14.
   Google Scholar
• Teichberg VI. From the liver to the brain across the blood-brain barrier. Proc Natl Acad Sci USA. 2007;104:7315–7316.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555–558.
   PubMed Web of Science ®Google Scholar
• Ferdinand P, Roffe C. Hypoxia after stroke: a review of experimental and clinical evidence. Exp Transl Stroke Med. 2016;8:9–0023.
   PubMedGoogle Scholar
• Adibhatla RM, Hatcher JF, Tureyen K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 2005;5:1–2.
   Google Scholar
• Siasios I, Kapsalaki EZ, Fountas KN. Cerebral vasospasm pharmacological treatment: an update. Neurol Res Int. 2013;571328:31.
   Google Scholar
• Vergouwen MDI, Etminan N, Ilodigwe D, et al. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2011;31:1545–1553.
   PubMed Web of Science ®Google Scholar
• Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014;2014:869269.
   PubMed Web of Science ®Google Scholar
• Patra JK, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:018–0392.
   PubMed Web of Science ®Google Scholar
• Yin KJ, Hamblin M, Chen YE. Angiogenesis-regulating microRNAs and Ischemic Stroke. Curr Vasc Pharmacol. 2015;13:352–365.
   PubMed Web of Science ®Google Scholar
• Li Q, He Q, Baral S, et al. MicroRNA-493 regulates angiogenesis in a rat model of ischemic stroke by targeting MIF. FEBS J. 2016;283:1720–1733.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang S, Wang Y, et al. Advances in self-assembled chitosan nanomaterials for drug delivery. Biotechnol Adv. 2014;32:1301–1316.
   PubMed Web of Science ®Google Scholar